Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : MET-X,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Venus Remedies
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Venus Remedies Licenses MET-X from Infex for India Market
Details : The agreement authorizes Venus Remedies to spearhead the clinical development, registration, and commercialization of MET-X, an innovative metallo-beta-lactamase (MBL) inhibitor.
Product Name : MET-X
Product Type : Antibiotic
Upfront Cash : Undisclosed
February 27, 2025
Lead Product(s) : MET-X,Meropenem
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Venus Remedies
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : MET-X
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Medivir Partner Infex Therapeutics Receives FDA QIDP Designation
Details : MET-X is a novel therapy designed to help restore the function of antibiotics that have become ineffective due to drug resistance created by bacterial enzymes known as metallo-β-lactamases (MBLs) which break down β-lactam antibiotics, including carbape...
Product Name : MET-X
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 11, 2023
Lead Product(s) : MET-X
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
